http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102670594-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6a6f422b091ba12ea61d4adbf1b0e8e |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4192 |
| filingDate | 2012-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fcdea18bebb8cab37a9d9c3b42669d4f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1894943e46769c92f75085e299aec380 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1067c41c20f2928561356fd26a8700a6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3878bd0d117d26bb2c8effcd2a07bfeb |
| publicationDate | 2014-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102670594-B |
| titleOfInvention | Appliance of 4site-1H-1,2,3- triazole-Beta-lactam derivatives for resisting liver cancer |
| abstract | The invention discloses an appliance of 4bit-1H-1,2,3- triazole-Beta-lactam derivatives for resisting liver cancer, wherein the 4bit-1H-1,2,3- triazole-Beta-lactam derivatives have excellent biological activity, have stronger value-added inhibitory activity to liver cancer cells HepG2 shown in testing of in-vitro activity, is a potential anti-cancer drug, and has the appliance for preparing anti-cancer drugs preparation. |
| priorityDate | 2012-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.